Mildronate decreases carnitine availability and up-regulates glucose uptake and related gene expression in the mouse heart

l-carnitine has been shown to play a central role in both fat and carbohydrate metabolisms. This study investigated whether acute and long-term treatments with an l-carnitine biosynthesis inhibitor, mildronate (3-(2,2,2-trimethylhydrazinium) propionate), modulate glucose uptake. The effects of acute...

Full description

Saved in:

Bibliographic Details
Published in:	Life sciences (1973) Vol. 83; no. 17; pp. 613 - 619
Main Authors:	Liepinsh, Edgars, Vilskersts, Reinis, Skapare, Elina, Svalbe, Baiba, Kuka, Janis, Cirule, Helena, Pugovics, Osvalds, Kalvinsh, Ivars, Dambrova, Maija
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Inc 24.10.2008
Subjects:	Animals Betaine - analogs & derivatives Betaine - analysis C-Peptide - analysis Cardiac energy metabolism Carnitine Carnitine - analysis Carnitine - metabolism Gene Expression Regulation - drug effects Glucose - metabolism Glucose Transporter Type 4 - genetics Glucose uptake Heart - drug effects Hexokinase - genetics Male Methylhydrazines - pharmacology Mice Mice, Inbred ICR Mildronate Myocardium - metabolism RNA, Messenger - analysis Up-Regulation FFA Cardiac energy metabolism HK II GLUT 4 INSR GBB PDC-E2 GLUT 1 PDC-E1 PDC Carnitine CPT IB LDH HDL Glucose uptake CPT IA FA Mildronate
ISSN:	0024-3205, 1879-0631
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	l-carnitine has been shown to play a central role in both fat and carbohydrate metabolisms. This study investigated whether acute and long-term treatments with an l-carnitine biosynthesis inhibitor, mildronate (3-(2,2,2-trimethylhydrazinium) propionate), modulate glucose uptake. The effects of acute and long-term administration of mildronate at a dose of 200 mg/kg (i.p. daily for 20 days) were tested in mouse blood plasma and heart. Acute administration of mildronate in vivo, or in vitro administration with perfusion buffer in isolated heart experiments, did not induce any effects on glucose blood concentration and uptake in the heart. Mildronate long-term treatment significantly decreased carnitine concentration in plasma and heart tissues, as well as increased the rate of insulin-stimulated glucose uptake by 35% and the expression of glucose transporter 4, hexokinase II, and insulin receptor proteins in mouse hearts. In addition, expression of both carnitine palmitoyltransferases IA and IB were significantly increased. Mildronate long-term treatment statistically significantly decreased fed state blood glucose from 6 ± 0.2 to 5 ± 0.1 mM, but did not affect plasma insulin and C-peptide levels. Our experiments demonstrate for the first time that long-term mildronate treatment decreases carnitine content in the mouse heart and leads to increased glucose uptake and glucose metabolism-related gene expression.
AbstractList	l-carnitine has been shown to play a central role in both fat and carbohydrate metabolisms. This study investigated whether acute and long-term treatments with an l-carnitine biosynthesis inhibitor, mildronate (3-(2,2,2-trimethylhydrazinium) propionate), modulate glucose uptake. The effects of acute and long-term administration of mildronate at a dose of 200 mg/kg (i.p. daily for 20 days) were tested in mouse blood plasma and heart. Acute administration of mildronate in vivo, or in vitro administration with perfusion buffer in isolated heart experiments, did not induce any effects on glucose blood concentration and uptake in the heart. Mildronate long-term treatment significantly decreased carnitine concentration in plasma and heart tissues, as well as increased the rate of insulin-stimulated glucose uptake by 35% and the expression of glucose transporter 4, hexokinase II, and insulin receptor proteins in mouse hearts. In addition, expression of both carnitine palmitoyltransferases IA and IB were significantly increased. Mildronate long-term treatment statistically significantly decreased fed state blood glucose from 6+/-0.2 to 5+/-0.1 mM, but did not affect plasma insulin and C-peptide levels. Our experiments demonstrate for the first time that long-term mildronate treatment decreases carnitine content in the mouse heart and leads to increased glucose uptake and glucose metabolism-related gene expression. Aims - l-carnitine has been shown to play a central role in both fat and carbohydrate metabolisms. This study investigated whether acute and long-term treatments with an l-carnitine biosynthesis inhibitor, mildronate (3-(2,2,2- trimethylhydrazinium) propionate), modulate glucose uptake. Main methods - The effects of acute and long-term administration of mildronate at a dose of 200 mg/kg (i.p. daily for 20 days) were tested in mouse blood plasma and heart. Key findings - Acute administration of mildronate in vivo, or in vitro administration with perfusion buffer in isolated heart experiments, did not induce any effects on glucose blood concentration and uptake in the heart. Mildronate long-term treatment significantly decreased carnitine concentration in plasma and heart tissues, as well as increased the rate of insulin-stimulated glucose uptake by 35% and the expression of glucose transporter 4, hexokinase, and insulin receptor proteins in mouse hearts. In addition, expression of both carnitine palmitoyltransferases IA and IB were significantly increased. Mildronate long-term treatment statistically significantly decreased fed state blood glucose from 6 +/- 0.2 to 5 +/- 0.1 mM, but did not affect plasma insulin and C-peptide levels. Significance - Our experiments demonstrate for the first time that long-term mildronate treatment decreases carnitine content in the mouse heart and leads to increased glucose uptake and glucose metabolism-related gene expression. l-carnitine has been shown to play a central role in both fat and carbohydrate metabolisms. This study investigated whether acute and long-term treatments with an l-carnitine biosynthesis inhibitor, mildronate (3-(2,2,2-trimethylhydrazinium) propionate), modulate glucose uptake. The effects of acute and long-term administration of mildronate at a dose of 200 mg/kg (i.p. daily for 20 days) were tested in mouse blood plasma and heart. Acute administration of mildronate in vivo, or in vitro administration with perfusion buffer in isolated heart experiments, did not induce any effects on glucose blood concentration and uptake in the heart. Mildronate long-term treatment significantly decreased carnitine concentration in plasma and heart tissues, as well as increased the rate of insulin-stimulated glucose uptake by 35% and the expression of glucose transporter 4, hexokinase II, and insulin receptor proteins in mouse hearts. In addition, expression of both carnitine palmitoyltransferases IA and IB were significantly increased. Mildronate long-term treatment statistically significantly decreased fed state blood glucose from 6 ± 0.2 to 5 ± 0.1 mM, but did not affect plasma insulin and C-peptide levels. Our experiments demonstrate for the first time that long-term mildronate treatment decreases carnitine content in the mouse heart and leads to increased glucose uptake and glucose metabolism-related gene expression. l-carnitine has been shown to play a central role in both fat and carbohydrate metabolisms. This study investigated whether acute and long-term treatments with an l-carnitine biosynthesis inhibitor, mildronate (3-(2,2,2-trimethylhydrazinium) propionate), modulate glucose uptake.AIMSl-carnitine has been shown to play a central role in both fat and carbohydrate metabolisms. This study investigated whether acute and long-term treatments with an l-carnitine biosynthesis inhibitor, mildronate (3-(2,2,2-trimethylhydrazinium) propionate), modulate glucose uptake.The effects of acute and long-term administration of mildronate at a dose of 200 mg/kg (i.p. daily for 20 days) were tested in mouse blood plasma and heart.MAIN METHODSThe effects of acute and long-term administration of mildronate at a dose of 200 mg/kg (i.p. daily for 20 days) were tested in mouse blood plasma and heart.Acute administration of mildronate in vivo, or in vitro administration with perfusion buffer in isolated heart experiments, did not induce any effects on glucose blood concentration and uptake in the heart. Mildronate long-term treatment significantly decreased carnitine concentration in plasma and heart tissues, as well as increased the rate of insulin-stimulated glucose uptake by 35% and the expression of glucose transporter 4, hexokinase II, and insulin receptor proteins in mouse hearts. In addition, expression of both carnitine palmitoyltransferases IA and IB were significantly increased. Mildronate long-term treatment statistically significantly decreased fed state blood glucose from 6+/-0.2 to 5+/-0.1 mM, but did not affect plasma insulin and C-peptide levels.KEY FINDINGSAcute administration of mildronate in vivo, or in vitro administration with perfusion buffer in isolated heart experiments, did not induce any effects on glucose blood concentration and uptake in the heart. Mildronate long-term treatment significantly decreased carnitine concentration in plasma and heart tissues, as well as increased the rate of insulin-stimulated glucose uptake by 35% and the expression of glucose transporter 4, hexokinase II, and insulin receptor proteins in mouse hearts. In addition, expression of both carnitine palmitoyltransferases IA and IB were significantly increased. Mildronate long-term treatment statistically significantly decreased fed state blood glucose from 6+/-0.2 to 5+/-0.1 mM, but did not affect plasma insulin and C-peptide levels.Our experiments demonstrate for the first time that long-term mildronate treatment decreases carnitine content in the mouse heart and leads to increased glucose uptake and glucose metabolism-related gene expression.SIGNIFICANCEOur experiments demonstrate for the first time that long-term mildronate treatment decreases carnitine content in the mouse heart and leads to increased glucose uptake and glucose metabolism-related gene expression.
Author	Kalvinsh, Ivars Svalbe, Baiba Kuka, Janis Liepinsh, Edgars Vilskersts, Reinis Pugovics, Osvalds Skapare, Elina Cirule, Helena Dambrova, Maija
Author_xml	– sequence: 1 givenname: Edgars surname: Liepinsh fullname: Liepinsh, Edgars email: ledgars@biomed.lu.lv – sequence: 2 givenname: Reinis surname: Vilskersts fullname: Vilskersts, Reinis – sequence: 3 givenname: Elina surname: Skapare fullname: Skapare, Elina – sequence: 4 givenname: Baiba surname: Svalbe fullname: Svalbe, Baiba – sequence: 5 givenname: Janis surname: Kuka fullname: Kuka, Janis – sequence: 6 givenname: Helena surname: Cirule fullname: Cirule, Helena – sequence: 7 givenname: Osvalds surname: Pugovics fullname: Pugovics, Osvalds – sequence: 8 givenname: Ivars surname: Kalvinsh fullname: Kalvinsh, Ivars – sequence: 9 givenname: Maija surname: Dambrova fullname: Dambrova, Maija
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/18801379$$D View this record in MEDLINE/PubMed
BookMark	eNqFkU2LFDEQhoOsuLOrP8CL5OStx3x2J3iSxS9Y8aLnkE6qZzNm0mOSXlx_vWln9eBhhYJA6nmK4q0LdJbmBAg9p2RLCe1f7bdxKltGiNquRdQjtKFq0B3pOT1DG0KY6Dgj8hxdlLInhEg58CfonCpFKB_0Bv38FKLPc7IVsAeXwRYo2NmcQg0JsL21IdoxxFDvsE0eL8cuw26JTSh4Fxc3F2if1X6D3_0Ma8vjHTQbfhwzlBLmhEPC9QbwYV4afwM216fo8WRjgWf37yX6-u7tl6sP3fXn9x-v3lx3TghVOy4k91oz2VOtBsd7K2DsR-2lliPj1jlNQYyDFKxnjnkugPNpmEYuPOF25Jfo5WnuMc_fFyjVHEJxEKNN0LYxve6V1Er8F6R60EJQ1sAX9-AyHsCbYw4Hm-_Mn1gbMJwAl-dSMkzGhWpry6HmlqehxKwHNHvTDmjWA5q1iGom_cf8O_wB5_XJgZbibYBsiguQHPiQwVXj5_CA_QvG2rTf
CitedBy_id	crossref_primary_10_3390_microorganisms13081751 crossref_primary_10_1097_FBP_0b013e32833d5a59 crossref_primary_10_1134_S1990750812020114 crossref_primary_10_1186_s12967_024_05222_7 crossref_primary_10_3389_fphar_2022_863451 crossref_primary_10_3390_ijms20225747 crossref_primary_10_1016_j_ejphar_2013_12_006 crossref_primary_10_1002_jcp_27602 crossref_primary_10_1111_j_1476_5381_2009_00319_x crossref_primary_10_3103_S0146411612020046 crossref_primary_10_1016_j_phrs_2014_05_002 crossref_primary_10_2478_v10143_011_0048_8 crossref_primary_10_1080_09291016_2018_1429552 crossref_primary_10_3390_antiox14060743 crossref_primary_10_1016_j_bbrc_2010_06_121 crossref_primary_10_1016_S1734_1140_11_70587_4 crossref_primary_10_1111_j_1472_8206_2011_00962_x crossref_primary_10_1007_s11011_022_01047_9 crossref_primary_10_1007_s40261_013_0121_x crossref_primary_10_1111_j_1742_7843_2009_00461_x crossref_primary_10_1016_j_hrthm_2015_07_027 crossref_primary_10_3390_ijms21197431 crossref_primary_10_3390_ijms23010045 crossref_primary_10_1177_1074248411419502 crossref_primary_10_1080_07391102_2024_2437528 crossref_primary_10_3390_ijms22062798 crossref_primary_10_1016_j_jbc_2023_105220 crossref_primary_10_1002_dta_2214 crossref_primary_10_1016_j_taap_2020_115031 crossref_primary_10_1007_s00392_017_1094_1 crossref_primary_10_1016_j_bbr_2011_03_027 crossref_primary_10_1007_s10557_009_6179_2 crossref_primary_10_1016_j_fsi_2017_07_058 crossref_primary_10_1016_j_phrs_2016_01_019 crossref_primary_10_1016_j_abb_2021_108892 crossref_primary_10_1007_s12012_012_9169_8 crossref_primary_10_1111_j_2042_7158_2011_01325_x crossref_primary_10_1111_1440_1681_12127 crossref_primary_10_1016_j_ajpath_2011_02_020 crossref_primary_10_1016_j_lfs_2014_09_028 crossref_primary_10_1016_j_livres_2024_09_001 crossref_primary_10_1038_s41598_020_80011_y crossref_primary_10_1002_cbf_1719 crossref_primary_10_1136_bjsports_2016_096357 crossref_primary_10_1016_j_metabol_2013_09_014 crossref_primary_10_1016_j_aquaculture_2021_736392 crossref_primary_10_1177_2397847320915143 crossref_primary_10_1007_s00394_011_0284_2 crossref_primary_10_1016_j_ejphar_2011_02_019 crossref_primary_10_3389_fphys_2018_00509 crossref_primary_10_1016_j_neulet_2009_12_055 crossref_primary_10_1113_JP274415
Cites_doi	10.1586/14779072.5.6.1123 10.1007/s00018-007-6359-9 10.1016/0026-0495(95)90058-6 10.1196/annals.1320.001 10.1161/01.CIR.0000012466.50373.E8 10.1161/CIRCULATIONAHA.107.702795 10.1016/0024-3205(95)02216-6 10.1111/j.1742-1241.2006.01280.x 10.1097/01.fjc.0000250077.07702.23 10.1161/01.RES.66.2.546 10.1161/hh2401.101385 10.1023/A:1006826620218 10.1016/j.cardfail.2007.07.007 10.1194/jlr.M200200-JLR200 10.1016/j.coph.2006.10.008 10.1074/jbc.M611391200 10.1113/jphysiol.2006.125799 10.1023/B:MCBI.0000012853.20116.06 10.1097/01.fjc.0000211732.76668.d2 10.1016/S1050-1738(02)00175-5 10.1016/S0021-9258(18)85410-2 10.1016/S0014-2999(00)00098-4 10.1111/j.1472-8206.1998.tb00936.x 10.1248/bpb.23.770 10.2337/diabetes.42.1.206 10.2337/diabetes.53.2.306 10.1016/0006-2952(88)90717-4 10.1046/j.1432-1327.2001.02065.x
ContentType	Journal Article
Copyright	2008 Elsevier Inc.
Copyright_xml	– notice: 2008 Elsevier Inc.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QO 8FD FR3 P64 RC3 7X8
DOI	10.1016/j.lfs.2008.08.008
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic
DatabaseTitleList	MEDLINE Genetics Abstracts MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Sciences (General) Biology
EISSN	1879-0631
EndPage	619
ExternalDocumentID	18801379 10_1016_j_lfs_2008_08_008 S0024320508003457
Genre	Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- --K --M -~X .55 .GJ .~1 0R~ 1B1 1RT 1~. 29L 3O- 4.4 457 53G 5GY 5RE 5VS 6TJ 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATCM AAXUO ABFNM ABFRF ABJNI ABLJU ABLVK ABMAC ABMZM ABTAH ABXDB ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACIWK ACPRK ACRLP ADBBV ADEZE ADMUD AEBSH AEFWE AEKER AENEX AFFNX AFKWA AFRAH AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 CNWQP CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMG HMT HVGLF HZ~ H~9 IH2 IHE J1W J5H K-O KOM L7B LCYCR M34 M41 MO0 MVM N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SDP SES SEW SIN SPCBC SPT SSH SSP SSZ T5K TEORI WUQ X7M Y6R YYP YZZ ZGI ZKB ZXP ZY4 ~G- 9DU AAHBH AATTM AAXKI AAYWO AAYXX ABUFD ABWVN ACIEU ACLOT ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGQPQ AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION EFKBS ~HD AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7QO 8FD FR3 P64 RC3 7X8
ID	FETCH-LOGICAL-c448t-3453d992561987c36a4eb6b9d595b23acc91e4b754262c2d34e33f7fb34d03ab3
ISICitedReferencesCount	58
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000260401700006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0024-3205
IngestDate	Sat Sep 27 18:02:04 EDT 2025 Tue Oct 07 09:21:25 EDT 2025 Mon Jul 21 06:04:55 EDT 2025 Sat Nov 29 06:40:24 EST 2025 Tue Nov 18 21:18:16 EST 2025 Fri Feb 23 02:29:52 EST 2024
IsPeerReviewed	true
IsScholarly	true
Issue	17
Keywords	FFA Cardiac energy metabolism HK II GLUT 4 INSR GBB PDC-E2 GLUT 1 PDC-E1 PDC Carnitine CPT IB LDH HDL Glucose uptake CPT IA FA Mildronate
Language	English
License	https://www.elsevier.com/tdm/userlicense/1.0
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c448t-3453d992561987c36a4eb6b9d595b23acc91e4b754262c2d34e33f7fb34d03ab3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
PMID	18801379
PQID	19794412
PQPubID	23462
PageCount	7
ParticipantIDs	proquest_miscellaneous_69685984 proquest_miscellaneous_19794412 pubmed_primary_18801379 crossref_citationtrail_10_1016_j_lfs_2008_08_008 crossref_primary_10_1016_j_lfs_2008_08_008 elsevier_sciencedirect_doi_10_1016_j_lfs_2008_08_008
PublicationCentury	2000
PublicationDate	2008-10-24
PublicationDateYYYYMMDD	2008-10-24
PublicationDate_xml	– month: 10 year: 2008 text: 2008-10-24 day: 24
PublicationDecade	2000
PublicationPlace	Netherlands
PublicationPlace_xml	– name: Netherlands
PublicationTitle	Life sciences (1973)
PublicationTitleAlternate	Life Sci
PublicationYear	2008
Publisher	Elsevier Inc
Publisher_xml	– name: Elsevier Inc
References	Fueger, Bracy, Malabanan, Pencek, Granner, Wasserman (bib10) 2004; 53 Morris, Zhou, Wolf, Christos, DiDomenico, Shug, Paulson (bib20) 1995; 57 Jonassen, Sack, Mjøs, Yellon (bib14) 2001; 89 Foster (bib8) 2004; 1033 Spaniol, Kaufmann, Beier, Wuthrich, Torok, Scharnagl, Marz, Krahenbuhl (bib25) 2003; 44 Dambrova, Liepinsh, Kalvinsh (bib5) 2002; 12 Lam, Lopaschuk (bib17) 2007; 7 Degrace, Demizieux, Du, Gresti, Caverot, Djaouti, Jourdan, Moindrot, Guilland, Hocquette, Clouet (bib6) 2007; 282 Simkhovich, Shutenko, Meirena, Khagi, Mezapuke, Molodchina, Kalvins, Lukevics (bib23) 1988; 37 Stephens, Constantin-Teodosiu, Greenhaff (bib26) 2007; 581 Ashrafian, Frenneaux, Opie (bib1) 2007; 116 Hayashi, Muranaka, Kirimoto, Asaka, Miyake, Matsuura (bib13) 2000; 23 Sesti, Simkhovich, Kalvinsh, Kloner (bib22) 2006; 47 Degrace, Demizieux, Gresti, Tsoko, Andre, Demaison, Clouet (bib7) 2004; 258 Kirimoto, Nobori, Asaka, Muranaka, Tajima, Miyake (bib16) 1996; 331 Liepinsh, Vilskersts, Loca, Kirjanova, Pugovichs, Kalvinsh, Dambrova (bib18) 2006; 48 Hayashi, Kirimoto, Asaka, Nakano, Tajima, Miyake, Matsuura (bib12) 2000; 395 Spaniol, Brooks, Auer, Zimmermann, Solioz, Stieger, Krahenbuhl (bib24) 2001; 268 Taegtmeyer, McNulty, Young (bib27) 2002; 105 Youngren (bib29) 2007; 64 Asaka, Muranaka, Kirimoto, Miyake (bib2) 1998; 12 Kamalesh (bib15) 2007; 13 Broderick, Christos, Wolf, DiDomenico, Shug, Paulson (bib4) 1995; 44 Benecke, Flier, Rosenthal, Siddle, Klein, Moller (bib3) 1993; 42 Hansen, Gulve, Marshall, Gao, Pessin, Holloszy, Mueckler (bib11) 1995; 270 Paulson (bib21) 1998; 180 Lopaschuk, Spafford, Davies, Wall (bib19) 1990; 66 Wang, Lopaschuk (bib28) 2007; 5 Fragasso (bib9) 2007; 61 Lopaschuk (10.1016/j.lfs.2008.08.008_bib19) 1990; 66 Paulson (10.1016/j.lfs.2008.08.008_bib21) 1998; 180 Stephens (10.1016/j.lfs.2008.08.008_bib26) 2007; 581 Sesti (10.1016/j.lfs.2008.08.008_bib22) 2006; 47 Wang (10.1016/j.lfs.2008.08.008_bib28) 2007; 5 Degrace (10.1016/j.lfs.2008.08.008_bib6) 2007; 282 Fueger (10.1016/j.lfs.2008.08.008_bib10) 2004; 53 Spaniol (10.1016/j.lfs.2008.08.008_bib25) 2003; 44 Youngren (10.1016/j.lfs.2008.08.008_bib29) 2007; 64 Hayashi (10.1016/j.lfs.2008.08.008_bib12) 2000; 395 Spaniol (10.1016/j.lfs.2008.08.008_bib24) 2001; 268 Kirimoto (10.1016/j.lfs.2008.08.008_bib16) 1996; 331 Taegtmeyer (10.1016/j.lfs.2008.08.008_bib27) 2002; 105 Hayashi (10.1016/j.lfs.2008.08.008_bib13) 2000; 23 Asaka (10.1016/j.lfs.2008.08.008_bib2) 1998; 12 Ashrafian (10.1016/j.lfs.2008.08.008_bib1) 2007; 116 Hansen (10.1016/j.lfs.2008.08.008_bib11) 1995; 270 Simkhovich (10.1016/j.lfs.2008.08.008_bib23) 1988; 37 Lam (10.1016/j.lfs.2008.08.008_bib17) 2007; 7 Kamalesh (10.1016/j.lfs.2008.08.008_bib15) 2007; 13 Fragasso (10.1016/j.lfs.2008.08.008_bib9) 2007; 61 Dambrova (10.1016/j.lfs.2008.08.008_bib5) 2002; 12 Foster (10.1016/j.lfs.2008.08.008_bib8) 2004; 1033 Degrace (10.1016/j.lfs.2008.08.008_bib7) 2004; 258 Liepinsh (10.1016/j.lfs.2008.08.008_bib18) 2006; 48 Morris (10.1016/j.lfs.2008.08.008_bib20) 1995; 57 Benecke (10.1016/j.lfs.2008.08.008_bib3) 1993; 42 Jonassen (10.1016/j.lfs.2008.08.008_bib14) 2001; 89 Broderick (10.1016/j.lfs.2008.08.008_bib4) 1995; 44
References_xml	– volume: 116 start-page: 434 year: 2007 end-page: 448 ident: bib1 article-title: Metabolic mechanisms in heart failure publication-title: Circulation – volume: 7 start-page: 179 year: 2007 end-page: 185 ident: bib17 article-title: Anti-anginal effects of partial fatty acid oxidation inhibitors publication-title: Current Opinion in Pharmacology – volume: 23 start-page: 770 year: 2000 end-page: 773 ident: bib13 article-title: Effects of MET-88 a gamma-butyrobetaine hydroxylase inhibitor on tissue carnitine and lipid levels in rats publication-title: Biological & Pharmaceutical Bulletin – volume: 57 start-page: 2237 year: 1995 end-page: 2244 ident: bib20 article-title: Sodium pivalate reduces cardiac carnitine content and increases glucose oxidation without affecting cardiac functional capacity publication-title: Life Sciences – volume: 180 start-page: 33 year: 1998 end-page: 41 ident: bib21 article-title: Carnitine deficiency-induced cardiomyopathy publication-title: Molecular and Cellular Biochemistry – volume: 270 start-page: 1679 year: 1995 end-page: 1684 ident: bib11 article-title: Skeletal muscle glucose transport and metabolism are enhanced in transgenic mice overexpressing the Glut4 glucose transporter publication-title: Journal of Biological Chemistry – volume: 258 start-page: 171 year: 2004 end-page: 182 ident: bib7 article-title: Fatty acid oxidation and related gene expression in heart depleted of carnitine by mildronate treatment in the rat publication-title: Molecular and Cellular Biochemistry – volume: 61 start-page: 603 year: 2007 end-page: 610 ident: bib9 article-title: Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure publication-title: International Journlal of Clinical Practice – volume: 66 start-page: 546 year: 1990 end-page: 553 ident: bib19 article-title: Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischemia publication-title: Circulation Research – volume: 44 start-page: 144 year: 2003 end-page: 153 ident: bib25 article-title: Mechanisms of liver steatosis in rats with systemic carnitine deficiency due to treatment with trimethylhydraziniumpropionate publication-title: Journal of Lipid Research – volume: 47 start-page: 493 year: 2006 end-page: 499 ident: bib22 article-title: Mildronate a novel fatty acid oxidation inhibitor and antianginal agent reduces myocardial infarct size without affecting hemodynamics publication-title: Journal of Cardiovascular Pharmacology – volume: 12 start-page: 158 year: 1998 end-page: 163 ident: bib2 article-title: Cardioprotective profile of MET-88 an inhibitor of carnitine synthesis and insulin during hypoxia in isolated perfused rat hearts publication-title: Fundamental and Clinical Pharmacology – volume: 12 start-page: 275 year: 2002 end-page: 279 ident: bib5 article-title: Mildronate: cardioprotective action through carnitine-lowering effect publication-title: Trends Cardiovascular Medicine – volume: 53 start-page: 306 year: 2004 end-page: 314 ident: bib10 article-title: Hexokinase II overexpression improves exercise-stimulated but not insulin-stimulated muscle glucose uptake in high-fat-fed C57BL/6J mice publication-title: Diabetes – volume: 44 start-page: 499 year: 1995 end-page: 505 ident: bib4 article-title: Fatty acid oxidation and cardiac function in the sodium pivalate model of secondary carnitine deficiency publication-title: Metabolism – volume: 48 start-page: 314 year: 2006 end-page: 319 ident: bib18 article-title: Mildronate an inhibitor of carnitine biosynthesis induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction publication-title: Journal of Cardiovascular Pharmacology – volume: 331 start-page: 163 year: 1996 end-page: 178 ident: bib16 article-title: Beneficial effect of MET-88 a gamma-butyrobetaine hydroxylase inhibitor on energy metabolism in ischemic dog hearts publication-title: Archives Internationales de Pharmacodynamie et de Therapie – volume: 581 start-page: 431 year: 2007 end-page: 444 ident: bib26 article-title: New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle publication-title: The Journal of Physiology – volume: 395 start-page: 217 year: 2000 end-page: 224 ident: bib12 article-title: Beneficial effects of MET-88 a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction publication-title: European Journal of Pharmacology – volume: 5 start-page: 1123 year: 2007 end-page: 1134 ident: bib28 article-title: Metabolic therapy for the treatment of ischemic heart disease: reality and expectations publication-title: Expert Review of Cardiovascular Therapy – volume: 282 start-page: 20816 year: 2007 end-page: 20826 ident: bib6 article-title: Regulation of lipid flux between liver and adipose tissue during transient hepatic steatosis in carnitine-depleted rats publication-title: Journal of Biological Chemistry – volume: 1033 start-page: 1 year: 2004 end-page: 16 ident: bib8 article-title: The role of the carnitine system in human metabolism publication-title: Annals of the New York Academy of Sciences – volume: 13 start-page: 861 year: 2007 end-page: 873 ident: bib15 article-title: Heart failure in diabetes and related conditions publication-title: Journal of Cardiac Failure – volume: 268 start-page: 1876 year: 2001 end-page: 1887 ident: bib24 article-title: Development and characterization of an animal model of carnitine deficiency publication-title: European Journal of Biochemistry – volume: 105 start-page: 1727 year: 2002 end-page: 1733 ident: bib27 article-title: Adaptation and maladaptation of the heart in diabetes: Part I: general concepts publication-title: Circulation – volume: 42 start-page: 206 year: 1993 end-page: 212 ident: bib3 article-title: Muscle-specific expression of human insulin receptor in transgenic mice publication-title: Diabetes – volume: 89 start-page: 1191 year: 2001 end-page: 1198 ident: bib14 article-title: Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling publication-title: Circulation Research – volume: 37 start-page: 195 year: 1988 end-page: 202 ident: bib23 article-title: 3-(222-Trimethylhydrazinium)propionate (THP)—a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties publication-title: Biochemical Pharmacology – volume: 64 start-page: 873 year: 2007 end-page: 891 ident: bib29 article-title: Regulation of insulin receptor function publication-title: Cellular and Molecular Life Sciences – volume: 5 start-page: 1123 issue: 6 year: 2007 ident: 10.1016/j.lfs.2008.08.008_bib28 article-title: Metabolic therapy for the treatment of ischemic heart disease: reality and expectations publication-title: Expert Review of Cardiovascular Therapy doi: 10.1586/14779072.5.6.1123 – volume: 64 start-page: 873 issue: 7–8 year: 2007 ident: 10.1016/j.lfs.2008.08.008_bib29 article-title: Regulation of insulin receptor function publication-title: Cellular and Molecular Life Sciences doi: 10.1007/s00018-007-6359-9 – volume: 44 start-page: 499 issue: 4 year: 1995 ident: 10.1016/j.lfs.2008.08.008_bib4 article-title: Fatty acid oxidation and cardiac function in the sodium pivalate model of secondary carnitine deficiency publication-title: Metabolism doi: 10.1016/0026-0495(95)90058-6 – volume: 1033 start-page: 1 year: 2004 ident: 10.1016/j.lfs.2008.08.008_bib8 article-title: The role of the carnitine system in human metabolism publication-title: Annals of the New York Academy of Sciences doi: 10.1196/annals.1320.001 – volume: 105 start-page: 1727 issue: 14 year: 2002 ident: 10.1016/j.lfs.2008.08.008_bib27 article-title: Adaptation and maladaptation of the heart in diabetes: Part I: general concepts publication-title: Circulation doi: 10.1161/01.CIR.0000012466.50373.E8 – volume: 116 start-page: 434 issue: 4 year: 2007 ident: 10.1016/j.lfs.2008.08.008_bib1 article-title: Metabolic mechanisms in heart failure publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.107.702795 – volume: 57 start-page: 2237 issue: 24 year: 1995 ident: 10.1016/j.lfs.2008.08.008_bib20 article-title: Sodium pivalate reduces cardiac carnitine content and increases glucose oxidation without affecting cardiac functional capacity publication-title: Life Sciences doi: 10.1016/0024-3205(95)02216-6 – volume: 61 start-page: 603 issue: 4 year: 2007 ident: 10.1016/j.lfs.2008.08.008_bib9 article-title: Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure publication-title: International Journlal of Clinical Practice doi: 10.1111/j.1742-1241.2006.01280.x – volume: 48 start-page: 314 issue: 6 year: 2006 ident: 10.1016/j.lfs.2008.08.008_bib18 article-title: Mildronate an inhibitor of carnitine biosynthesis induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction publication-title: Journal of Cardiovascular Pharmacology doi: 10.1097/01.fjc.0000250077.07702.23 – volume: 66 start-page: 546 issue: 2 year: 1990 ident: 10.1016/j.lfs.2008.08.008_bib19 article-title: Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischemia publication-title: Circulation Research doi: 10.1161/01.RES.66.2.546 – volume: 89 start-page: 1191 issue: 12 year: 2001 ident: 10.1016/j.lfs.2008.08.008_bib14 article-title: Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling publication-title: Circulation Research doi: 10.1161/hh2401.101385 – volume: 180 start-page: 33 issue: 1–2 year: 1998 ident: 10.1016/j.lfs.2008.08.008_bib21 article-title: Carnitine deficiency-induced cardiomyopathy publication-title: Molecular and Cellular Biochemistry doi: 10.1023/A:1006826620218 – volume: 13 start-page: 861 issue: 10 year: 2007 ident: 10.1016/j.lfs.2008.08.008_bib15 article-title: Heart failure in diabetes and related conditions publication-title: Journal of Cardiac Failure doi: 10.1016/j.cardfail.2007.07.007 – volume: 44 start-page: 144 issue: 1 year: 2003 ident: 10.1016/j.lfs.2008.08.008_bib25 article-title: Mechanisms of liver steatosis in rats with systemic carnitine deficiency due to treatment with trimethylhydraziniumpropionate publication-title: Journal of Lipid Research doi: 10.1194/jlr.M200200-JLR200 – volume: 7 start-page: 179 issue: 2 year: 2007 ident: 10.1016/j.lfs.2008.08.008_bib17 article-title: Anti-anginal effects of partial fatty acid oxidation inhibitors publication-title: Current Opinion in Pharmacology doi: 10.1016/j.coph.2006.10.008 – volume: 282 start-page: 20816 issue: 29 year: 2007 ident: 10.1016/j.lfs.2008.08.008_bib6 article-title: Regulation of lipid flux between liver and adipose tissue during transient hepatic steatosis in carnitine-depleted rats publication-title: Journal of Biological Chemistry doi: 10.1074/jbc.M611391200 – volume: 581 start-page: 431 issue: Pt 2 year: 2007 ident: 10.1016/j.lfs.2008.08.008_bib26 article-title: New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle publication-title: The Journal of Physiology doi: 10.1113/jphysiol.2006.125799 – volume: 258 start-page: 171 issue: 1–2 year: 2004 ident: 10.1016/j.lfs.2008.08.008_bib7 article-title: Fatty acid oxidation and related gene expression in heart depleted of carnitine by mildronate treatment in the rat publication-title: Molecular and Cellular Biochemistry doi: 10.1023/B:MCBI.0000012853.20116.06 – volume: 47 start-page: 493 issue: 3 year: 2006 ident: 10.1016/j.lfs.2008.08.008_bib22 article-title: Mildronate a novel fatty acid oxidation inhibitor and antianginal agent reduces myocardial infarct size without affecting hemodynamics publication-title: Journal of Cardiovascular Pharmacology doi: 10.1097/01.fjc.0000211732.76668.d2 – volume: 12 start-page: 275 issue: 6 year: 2002 ident: 10.1016/j.lfs.2008.08.008_bib5 article-title: Mildronate: cardioprotective action through carnitine-lowering effect publication-title: Trends Cardiovascular Medicine doi: 10.1016/S1050-1738(02)00175-5 – volume: 270 start-page: 1679 issue: 4 year: 1995 ident: 10.1016/j.lfs.2008.08.008_bib11 article-title: Skeletal muscle glucose transport and metabolism are enhanced in transgenic mice overexpressing the Glut4 glucose transporter publication-title: Journal of Biological Chemistry doi: 10.1016/S0021-9258(18)85410-2 – volume: 331 start-page: 163 issue: 2 year: 1996 ident: 10.1016/j.lfs.2008.08.008_bib16 article-title: Beneficial effect of MET-88 a gamma-butyrobetaine hydroxylase inhibitor on energy metabolism in ischemic dog hearts publication-title: Archives Internationales de Pharmacodynamie et de Therapie – volume: 395 start-page: 217 issue: 3 year: 2000 ident: 10.1016/j.lfs.2008.08.008_bib12 article-title: Beneficial effects of MET-88 a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction publication-title: European Journal of Pharmacology doi: 10.1016/S0014-2999(00)00098-4 – volume: 12 start-page: 158 issue: 2 year: 1998 ident: 10.1016/j.lfs.2008.08.008_bib2 article-title: Cardioprotective profile of MET-88 an inhibitor of carnitine synthesis and insulin during hypoxia in isolated perfused rat hearts publication-title: Fundamental and Clinical Pharmacology doi: 10.1111/j.1472-8206.1998.tb00936.x – volume: 23 start-page: 770 issue: 6 year: 2000 ident: 10.1016/j.lfs.2008.08.008_bib13 article-title: Effects of MET-88 a gamma-butyrobetaine hydroxylase inhibitor on tissue carnitine and lipid levels in rats publication-title: Biological & Pharmaceutical Bulletin doi: 10.1248/bpb.23.770 – volume: 42 start-page: 206 issue: 1 year: 1993 ident: 10.1016/j.lfs.2008.08.008_bib3 article-title: Muscle-specific expression of human insulin receptor in transgenic mice publication-title: Diabetes doi: 10.2337/diabetes.42.1.206 – volume: 53 start-page: 306 issue: 2 year: 2004 ident: 10.1016/j.lfs.2008.08.008_bib10 article-title: Hexokinase II overexpression improves exercise-stimulated but not insulin-stimulated muscle glucose uptake in high-fat-fed C57BL/6J mice publication-title: Diabetes doi: 10.2337/diabetes.53.2.306 – volume: 37 start-page: 195 issue: 2 year: 1988 ident: 10.1016/j.lfs.2008.08.008_bib23 article-title: 3-(222-Trimethylhydrazinium)propionate (THP)—a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties publication-title: Biochemical Pharmacology doi: 10.1016/0006-2952(88)90717-4 – volume: 268 start-page: 1876 issue: 6 year: 2001 ident: 10.1016/j.lfs.2008.08.008_bib24 article-title: Development and characterization of an animal model of carnitine deficiency publication-title: European Journal of Biochemistry doi: 10.1046/j.1432-1327.2001.02065.x
SSID	ssj0005573
Score	2.1584296
Snippet	l-carnitine has been shown to play a central role in both fat and carbohydrate metabolisms. This study investigated whether acute and long-term treatments with... Aims - l-carnitine has been shown to play a central role in both fat and carbohydrate metabolisms. This study investigated whether acute and long-term...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	613
SubjectTerms	Animals Betaine - analogs & derivatives Betaine - analysis C-Peptide - analysis Cardiac energy metabolism Carnitine Carnitine - analysis Carnitine - metabolism Gene Expression Regulation - drug effects Glucose - metabolism Glucose Transporter Type 4 - genetics Glucose uptake Heart - drug effects Hexokinase - genetics Male Methylhydrazines - pharmacology Mice Mice, Inbred ICR Mildronate Myocardium - metabolism RNA, Messenger - analysis Up-Regulation
Title	Mildronate decreases carnitine availability and up-regulates glucose uptake and related gene expression in the mouse heart
URI	https://dx.doi.org/10.1016/j.lfs.2008.08.008 https://www.ncbi.nlm.nih.gov/pubmed/18801379 https://www.proquest.com/docview/19794412 https://www.proquest.com/docview/69685984
Volume	83
WOSCitedRecordID	wos000260401700006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1879-0631 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005573 issn: 0024-3205 databaseCode: AIEXJ dateStart: 19950106 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaWLUhcEC2vLVB84MBDqdLYSexjhRYBKhUSBe0tsh0HpY3S1b5U-GP8PWZiJ9kWbUUPSKtolXWyjueLZzz-ZoaQlzy3ulAmDgptYIHCcxMAbkSgCpGI1LJQy6IpNpEeH4vJRH4ZDH63sTCrKq1rcXEhp_9V1HAOhI2hszcQd3dTOAHfQehwBLHD8Z8E_xmjs9EnjhFRaBPObZOAGllCYFGqlSorl5zbpV5aToOZK0gP7VoG-3K6UGduZ6GJdgGzFP7QYkEAR5ztCJLoOrBob1728h-VhX3r1avLBiXTdafuUWmxaHbj1BnnP1S_qfS9rOZnaJQ6H5D1uU98qTCFjHnPR6s7lfIVBlBbt39SanXJldHklXUR1F1oAQ9YFMbr07Orc9PCMA38dO3m28QFsnrVnbjZ9y-t4BwUp_tVMffsWSTQil4Fttv-VzRjx1dsqXCnGdzCV-6EDwaZb0VpLMWQbB1-HE8-9eyi2JMb_BO1G-oNtfBKPzaZRJuWPI3pc3Kf3PNrFnrosLZNBrbeIXdcFdOfO2Tb64c5feWTmL9-QH71MKQdDGkHQ7oOQwowo-swpB6G1MGw-d3DkCIMaQ9DWtYUYEgbGNIGhg_Jt_fjk3cfAl_nIzCci0XAeMxyKcH4Rg-YYYniVida5rGMdcSUMfLAco21mpPIRDnjlrEiLTTjeciUZo_IsD6v7RNClU5MyLRWSmEdHSFiWYCFbDRY_bASsiMStkOdGZ8EH2uxVNlGEY_Im-6SqcsAc11j3sov8--YM00zwOJ1l71oZZ3B9I57dqq2MHAZvJwS-h5tboHZrQCBfEQeO5D0vQTdfMBSuXuTJ3hK7vav5jMyXMyW9jm5bVaLcj7bI7fSidjzYP8D2yHf0A
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mildronate+decreases+carnitine+availability+and+up-regulates+glucose+uptake+and+related+gene+expression+in+the+mouse+heart&rft.jtitle=Life+sciences+%281973%29&rft.au=Liepinsh%2C+Edgars&rft.au=Vilskersts%2C+Reinis&rft.au=Skapare%2C+Elina&rft.au=Svalbe%2C+Baiba&rft.date=2008-10-24&rft.issn=0024-3205&rft.volume=83&rft.issue=17-18&rft.spage=613&rft.epage=619&rft_id=info:doi/10.1016%2Fj.lfs.2008.08.008&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_lfs_2008_08_008
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0024-3205&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0024-3205&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0024-3205&client=summon